You can buy or sell MediciNova and other stocks, options, ETFs, and crypto commission-free!
Medicinova Inc Common Stock, also called MediciNova, is a biopharmaceutical company. It is engaged in acquiring and developing novel, small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. Read More The firm's development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
La Jolla, California
52 Week High
52 Week Low
Simply Wall StMar 8
Is MediciNova’s (NASDAQ:MNOV) Share Price Gain Of 282% Well Earned?
The MediciNova, Inc. (NASDAQ:MNOV) share price has had a bad week, falling 11%. But in stark contrast, the returns over the last half decade have impressed. In fact, the share price is 282% higher today. We think it’s more important to dwell on the long term returns than the short term returns. Only time will tell if there is still too much optimism currently reflected in the share price. Check out our latest analysis for MediciNova With zero revenue generated over twelve months, we MediciNova has proved ...
Associated PressMar 5
MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan
LA JOLLA, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive research collaboration to evaluate MN-001 (tipelukast) in liver diseases with the Division of Gastroenterology and Hepatology at The Jikei University School of Medicine in Tokyo, Japan. Yuichi Iwaki, M.D., Ph.D., President and Chief Execu...
Stock Price, News, & Analysis for MediciNova
News coverage about MNOV stock has been trending positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MediciNova earned a daily sentiment score of 2.8 on InfoTrie's scale. They also assigned news stories about the biopharmaceut...
Expected Apr 25, After Hours